New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was −$6.4M: capital expenditures were more than operating cash flow. Cash rose by $6.5M. Lines the picture does not name came to +$12.9M. What is a cash flow statement?

Free cash flow
−$6.4M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$6.5M over the period
Where the cash went, in millions of dollars
Operating cash flow−6.4
Free cash flow−6.4
Other+12.9
Change in cash6.5

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more quarters

(7.27) (6.80) (6.46) (6.12)
Depreciation & Amortization
(0.18) 0.02 0.02 0.02
Non Cash Items (Other)
0.54 0.36 0.34 0.41
Change in payables and accrued liability
0.00 0.21 (2.15) (1.11)
Change in other assets and liabilities
1.23 0.35 (0.99) 0.42
Operating Cash Flow
(5.68) (5.86) (9.23) (6.38)
Short Term Investments Change (Net)
5.00 4.98 5.14 0.00
Investing cash flow
5.00 4.98 5.14 0.00
Equity Repurchase (Common, Net)
0.00 — — —
Other financial activities
0.00 — — —
Financing cash flow
0.00 — — —
Change in Cash
(0.68) (0.88) (4.09) 6.51
Beginning Cash
0.00 20.73 0.00 0.00
Ending Cash
(0.68) 19.85 (4.09) 6.51
Stock Based Compensation
0.35 0.37 0.34 0.39
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
1.23 0.57 (3.13) (0.69)
Investments Change (Net)
5.00 4.98 5.14 0.00
Issuance/Purchase of Shares
0.00 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026